Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe
EntityUAM. Departamento de Medicina Preventiva y Salud Pública y Microbiología
PublisherPublic Library of Science
10.1371/journal.pone.0115270PlLos ONE 10.2 (2015): e0115270
Funded byWriting support was provided by Oxford PharmaGenesis Ltd, Oxford, UK, and was funded by AstraZeneca
SubjectsDyslipidaemia; Cardiovascular risk; EURIKA; Lipid-lowering therapy; Medicina
Rights© 2015 Halcox et al.
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional.
Aims To analyse the treatment and control of dyslipidaemia in patients at high and very high cardiovascular risk being treated for the primary prevention of cardiovascular disease (CVD) in Europe. Methods and Results Data were assessed from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA, ClinicalTrials.gov identifier: NCT00882336), which included a randomly sampled population of primary CVD prevention patients from 12 European countries (n = 7641). Patients’ 10-year risk of CVD-related mortality was calculated using the Systematic Coronary Risk Evaluation (SCORE) algorithm, identifying 5019 patients at high cardiovascular risk (SCORE 5% and/or receiving lipid-lowering therapy), and 2970 patients at very high cardiovascular risk (SCORE 10% or with diabetes mellitus). Among high-risk individuals, 65.3% were receiving lipid-lowering therapy, and 61.3% of treated patients had uncontrolled low-density lipoprotein cholesterol (LDL-C) levels ( 2.5 mmol/L). For very-high-risk patients (uncontrolled LDL-C levels defined as 1.8 mmol/L) these figures were 49.5% and 82.9%, respectively. Excess 10-year risk of CVD-related mortality (according to SCORE) attributable to lack of control of dyslipidaemia was estimated to be 0.72%and 1.61% among high-risk and very-high-risk patients, respectively. Among high-risk individuals with uncontrolled LDL-C levels, only 8.7% were receiving a high-intensity statin (atorvastatin 40 mg/day or rosuvastatin 20 mg/day). Among veryhigh- risk patients, this figure was 8.4%. Conclusions There is a considerable opportunity for improvement in rates of lipid-lowering therapy use and achievement of lipid-level targets in high-risk and very-high-risk patients being treated for primary CVD prevention in Europe
Google Scholar:Halcox, Julian P. - Tubach, Florence - López García, Esther - De Backer, Guy - Borghi, Claudio - Dallongeville, Jean - Guallar, Eliseo - Medina, Jesús - Perk, Joep - Sazova, Ogün - Sweet, Stephen - Roy, Carine - Banegas Banegas, José Ramón - Rodríguez Artalejo, Fernando
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study Guallar, Eliseo; Banegas Banegas, José Ramón; Blasco-Colmenares, Elena; Jiménez, Francisco Javier Gómez; Dallongeville, Jean; Halcox, Julian PJ J; Borghi, Claudio; Massó-González, Elvira L.; Tafalla, Mónica; Perk, Joep; De Backer, Guy G.; Steg, Philippe Gabriel; Rodríguez Artalejo, Fernando